ClinicalTrials.Veeva

Menu

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma

P

Peking University Cancer Hospital & Institute

Status

Unknown

Conditions

Lymphoma, Large B-Cell, Diffuse

Treatments

Device: 18F-FDG PET/CT

Study type

Interventional

Funder types

Other

Identifiers

NCT02928861
XW-DLBCL-002

Details and patient eligibility

About

The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of diffuse large B-cell lymphoma can predict disease progression

Full description

In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold (1.6 fold of liver SUVmax) or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in DLBCL.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. newly diagnosed DLBCL;
  2. treated using an anthracycline-containing regimen with or without rituximab;
  3. minimal follow-up at 6 months after the completion of first-line treatment;
  4. complete medical history and clinicopathological data

Exclusion criteria

  1. secondary malignant disease;
  2. serious infection or inflammation (e.g., HIV);
  3. primary central nervous system lymphoma;
  4. hepatic or renal dysfunction.

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

100 participants in 1 patient group

18F-FDG PET/CT-based prognostic model
Experimental group
Description:
The new prognostic model is based on 18F-FDG PET/CT scans, and combined with clinical and pathological prognostic factors.
Treatment:
Device: 18F-FDG PET/CT

Trial contacts and locations

2

Loading...

Central trial contact

Xuejuan Wang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems